Axcan has completed its acquisition of Eurand N.V., a global specialty pharmaceutical company with operating units in the United States and Europe. In a February 11 letter, Axcan President and CEO Frank Verwiel explained how the merger will affect its customers:

Dear Customer:

We are pleased to announce, effective immediately, the combination of two leading specialty pharmaceutical companies focused on improving the quality of care and health of our patients. Based on the acquisition of Eurand by Axcan, the operations of both companies will be merged.

 

Combining our strengths will result in a global specialty pharmaceutical company with complementary GI and CF capabilities, a diversified and strengthened product and technology portfolio, broader development pipeline, an expanded manufacturing footprint and enhanced R&D capabilities. Most importantly, this merger will enhance our ability to meet the needs of the patients and caregivers we serve by bringing together our world-class talent, technologies, and brands. These brands include our portfolio of products for patients with Cystic Fibrosis, such as ZENPEP®, Scandishake®, and the AquADEKs™ and SourceCF® Multivitamin lines.

 

The process of integrating our two companies is underway, but in the meantime, each of the respective companies will be operating as before, without interruption to the high level of service and support that you expect and deserve. Therefore, at this time, your existing relationships will remain the same. As part of this transition, we will be exploring new ways to enhance our popular comprehensive patient support program, ZPoints®, to take advantage of our new combined resources. We will let you know if there are any changes that may impact you at any point in the near future. We are committed to maintaining business continuity and a seamless customer experience throughout the integration process. Please contact your current representative with any questions.

 

Stronger together, Axcan and Eurand will create a remarkable organization designed to serve the evolving needs of our patients and caregivers. We value your business and look forward to continuing to work with you to improve the lives of patients with Cystic Fibrosis.

 

Sincerely,

 

Frank Verwiel, MD

President and Chief Executive Officer

« Previous Page